Document:

Exhibit 10.01

 

	Shire plc	 
	5 Riverwalk
	Citywest Business Campus
	Dublin 24
	Ireland
	www.shire.com

 

 

 

PRIVATE AND CONFIDENTIAL

 

European Loans Agency

Barclays Bank PLC

5 The North Colonnade

Canary Wharf

London E14 4BB

For the attention of: Simon Deaves

 

4 November 2015

 

CONSENT REQUEST

 

US$2,100,000,000 multicurrency revolving
and swingline facilities agreement dated

12 December 2014

 

		1.	Introduction

 

		1.1	We refer to the US$2,100,000,000 multicurrency revolving and
swingline facilities agreement dated 12 December 2014 between, among others, Shire plc (the “Company”)
as an Original Borrower and an Original Guarantor and Barclays Bank PLC as Facility Agent (the “Facilities Agreement”).

 

		1.2	Save as otherwise defined in this letter, terms and expressions
defined in the Facilities Agreement shall have the same meaning when used in this letter. 

 

		1.3	We are writing to you in your capacity as Facility Agent pursuant
to and in accordance with Clause 42.1 (Required consents) of the Facilities Agreement to request that the Majority Lenders
agree to the amendments described in paragraph 2 of this letter, any such amendment to become effective upon the Facility Agent
giving the Company a signed notice in the form set out in Schedule 3 (Form of Request Approval Notice) (a “Request
Approval Notice”) and the Obligors accepting such Request Approval Notice by signing, dating,
and returning a copy thereof to the Facility Agent. 

 

		2.	Requests

 

		2.1	Acquisition Spike 

 

We hereby
request that paragraph (A) of Clause 27.2 (Financial condition) of the Facilities Agreement be amended to reflect the changes
shown in the redline set out in Schedule 1 (Financial condition) (the “First Requested Amendment”).

 

		2.2	Clean-up Period

 

We
hereby request that Clause 30.13 (Clean-up Period) of the Facilities Agreement be amended to reflect the changes shown in
the redline set out in Schedule 2 (Clean-up Period) (the “Second Requested Amendment”).

 

    

    2

    

These amendments are requested in order to align
the wording of these clauses with the wording in the equivalent clauses in Shire’s US$5,600,000,000 term loan facilities.

 

		3.	Timing of consents

 

		3.1	A response is requested by 5:00 pm on 20 November 2015 (the “Request
Deadline”).

 

		3.2	If, by the Request Deadline, the Majority Lenders have provided
their consent to the First Requested Amendment, the Second Requested Amendment, or both, the Facility Agent shall deliver to the
Company a Request Approval Notice. 

 

		3.3	If, by the Request Deadline, the Facility Agent has not given
the Company a Request Approval Notice, the Company reserves the right to extend the Request Deadline or, after the expiry of the
Request Deadline (whether or not extended), to re-open this consent request (and, if necessary or desirable, amend the content
of this consent request) and set a new deadline. 

 

		4.	Miscellaneous

 

By providing a Request Approval
Notice, you agree in your capacity as Facility Agent that this letter is a Finance Document for the purposes of the Facilities
Agreement.

 

		5.	Governing Law and Enforcement

 

The provisions of clause 46
(Governing law) and clause 47 (Enforcement) of the Facilities Agreement are incorporated into this letter as though
they were set out in full, except that references to the Facilities Agreement are to be construed as references to this letter.

 

 

 

 

Yours faithfully

 

	/s/ Jeff Poulton

for and on behalf of

Shire plc

 

    

    3

    

SCHEDULE 1

 

FINANCIAL
CONDITION

 

		(A)	the
                                         ratio of Net Debt to EBITDA of the Group in respect of the most recently ended Relevant
                                         Period (the "Leverage Ratio") shall not at any time exceed 3.5:1, except
                                         that, following an acquisition by the Group (other
                                         than an In-licensing Acquisition (as defined below)) for a consideration which
                                         includes a cash element of at least US$ 250,000,000, the Parent Company may elect
                                         to increase the Leverage Ratio to 4.0:1 for:

 

		(i)	in
                                         respect of the Relevant Period in which the acquisition
                                         was completed and the immediately following Relevant Period (except in the case
                                         of an In-licensing Acquisition (as defined below)). ,
                                         to increase the maximum allowable Leverage Ratio to 5.5:1;

 

		(ii)	in
                                         respect of the first Relevant Period immediately following the Relevant Period referred
                                         to in paragraph (i) above, to increase the maximum allowable Leverage Ratio to 5.0:1;
                                         and

 

		(iii)	in
                                         respect of the second Relevant Period immediately following the Relevant Period referred
                                         to in paragraph (i) above, to increase the maximum allowable Leverage Ratio to 4.5:1.

 

The
election must be made by no later than the date on which the Compliance Certificate for the first Relevant Period to which that
election relates is delivered pursuant to Clause 26.2 (Compliance Certificate) (or the date on which such Compliance Certificate
was due to have been delivered if earlier). For the avoidance of doubt, an “acquisition”
includes an in-licensing agreement under which the Group acquires certain rights to products and projects (an "In-licensing
Acquisition") which would require the Group to pay licence fees, milestone payments or other similar fees or payments
("In-licensing Fees and Payments"). Notwithstanding the above, where the acquisition is an In-licensing Acquisition
the Parent Company may elect to increase the maximum allowable Leverage
Ratio to 4.0:1as set out above where the aggregate In-licensing
Fees and Payments in respect of that In-licensing Acquisition totals at least US$ 250,000,000 in any one Relevant Period. The
increase in the maximum allowable Leverage Ratio shall apply to the Relevant
Period in which such In-licensing Fees and Payments were paid and the immediately followingsubsequent
Relevant PeriodPeriods as set out above and
the election must be made by no later than the date on which the Compliance Certificate for the first Relevant Period to which
that election relates is delivered pursuant to Clause 26.2 (Compliance Certificate) (or the date on which such Compliance
Certificate was due to have been delivered if earlier). Only one election under this paragraph (A) may be made; and

 

    

    4

    

SCHEDULE 2

 

CLEAN-UP PERIOD

 

Notwithstanding any other
provision of this Agreement, if, during any period (each, a "Clean-up Period") of threesix months
from (and including) the date on which a member of the Group becomes the owner of record of the shares or other assets which
are the subject of any acquisition after the date of this Agreement, any event or circumstance arises or becomes apparent
which would otherwise constitute a Default or an Event of Default (other than under Clause 30.1 (Non-payment)) (a
"Clean-up Default"), that Clean-up Default will not, during the relevant Clean-up Period:

 

		(i)	constitute a Default or an Event of Default (or any other actual or potential breach of any term
of this Agreement);

 

		(ii)	operate to prevent any Utilisation or the making of any Loan; or

 

		(iii)	allow any Finance Party to accelerate or take any other action contemplated by Clause 30.14 (Acceleration)
or to take any enforcement action,

 

provided that the Clean-up
Default:

 

		(a)	is capable of remedy within the Clean-up Period and reasonable steps are taken to remedy it;

 

		(b)	relates to the target company or target undertaking of that acquisition or the Subsidiaries of
such target company or target undertaking; and (it being understood
that, for these purposes, any Clean-up Default which arises under Clause 30.5 (Cross default) in connection with any Financial
Indebtedness of such target company or target undertaking or the Subsidiaries of such target company or target undertaking shall
be deemed to relate to such entities); and

 

(c)is not reasonably likely
to have a Material Adverse Effect.

 

    

    5

    

SCHEDULE 3

 

FORM OF REQUEST APPROVAL NOTICE

 

PRIVATE AND CONFIDENTIAL

 

Shire plc (the “Company”)

5 Riverwalk

Citywest Business Campus

Dublin 24

Ireland

 

For the attention of: Thomas Greene

 

____November 2015

 

SHIRE PLC - CONSENT REQUEST APPROVAL NOTICE

 

		1.	We refer to:

 

		(A)	the US$2,100,000,000 multicurrency revolving and swingline facilities agreement dated 12 December
2014 between, among others, the Company as an Original Borrower and an Original Guarantor and Barclays Bank PLC as Facility Agent
(the “Facilities Agreement”); and

 

		(B)	your letter to us dated 4 November 2015 in which you requested that the Majority Lenders agree
to amendments of certain provisions of the Facilities Agreement (the “Consent Request”).

 

		2.	Unless otherwise defined, terms and expressions defined in the
Facilities Agreement or in the Consent Request shall have the same meaning when used in this letter. 

 

		3.	We confirm that we have received the consent of the Majority
Lenders to the First Requested Amendment and the Second Requested Amendment (the “Approved Amendments”)
and consequently that the Approved Amendments shall, provided that you and the other Obligors sign, date and return to us a copy
of this letter in accordance with paragraph 1.3 of the Consent Request, become effective immediately and automatically, and from
that date the Facilities Agreement and the Consent Request shall be read and construed as one document to the extent of the Approved
Amendments.

 

		4.	Please confirm your agreement to the terms of this letter by
signing, dating and returning a copy thereof. 

 

		5.	This letter may be executed in any number of counterparts and
this has the same effect as if the signatures on the counterparts were on a single copy of this letter. 

 

		6.	This letter is a Finance Document. 

 

		7.	The provisions of clause 46 (Governing law) and
clause 47 (Enforcement) of the Facilities Agreement are incorporated into this letter as though they were set out in full,
except that references to the Facilities Agreement are to be construed as references to this letter.

 

 

Yours faithfully

 

	  

for and on behalf of

Barclays Bank PLC

as Facility Agent, for itself and on behalf of each of the Finance Parties

 

    

    6

    

SHIRE PLC CONSENT REQUEST APPROVAL NOTICE SIGNATURE PAGE

 

 

Acknowledged and agreed

 

 

 

	  

for and on behalf of

Shire plc

 

 

 

	  

for and on behalf of

Shire Global Finance

 

 

 

	  

for and on behalf of

Shire Biopharmaceuticals Holdings

 

 

 

	  

for and on behalf of

Shire Holdings Europe No. 2 S.à r.l.

 

 

 

	  

for and on behalf of

Shire Holdings Luxembourg S.à r.l.

 

 

 

	  

for and on behalf of

Shire Pharmaceutical Holdings Ireland Limited

 

Date:Exhibit 10.02

 

 

	 	5
    The North Colonnade
	 	Canary
    Wharf
	 	London
    E14 4BB
	 	United
    Kingdom
	 	 
	PRIVATE
    AND CONFIDENTIAL	Tel    +44
    (0)20 7623 2323
	 	 
	Shire
    plc (the “Company”)	 
	5
    Riverwalk	barclays.com
	Citywest
    Business Campus	 
	Dublin
    24	 
	Ireland	 

 

For the attention of: Thomas Greene

 

20th November
2015

 

SHIRE PLC - CONSENT REQUEST APPROVAL NOTICE

 

		1.	We refer to:

 

		(A)	the US$2,100,000,000 multicurrency revolving and swingline facilities agreement dated 12 December
2014 between, among others, the Company as an Original Borrower and an Original Guarantor and Barclays Bank PLC as Facility Agent
(the “Facilities Agreement”); and

 

		(B)	your letter to us dated 4 November 2015 in which you requested that the Majority Lenders agree
to amendments of certain provisions of the Facilities Agreement (the “Consent Request”).

 

		2.	Unless otherwise defined, terms and expressions defined in the
Facilities Agreement or in the Consent Request shall have the same meaning when used in this letter. 

 

		3.	We confirm that we have received the consent of the Majority
Lenders to the First Requested Amendment and the Second Requested Amendment (the “Approved Amendments”)
and consequently that the Approved Amendments shall, provided that you and the other Obligors sign, date and return to us a copy
of this letter in accordance with paragraph 1.3 of the Consent Request, become effective immediately and automatically, and from
that date the Facilities Agreement and the Consent Request shall be read and construed as one document to the extent of the Approved
Amendments.

 

		4.	Please confirm your agreement to the terms of this letter by
signing, dating and returning a copy thereof. 

 

		5.	This letter may be executed in any number of counterparts and
this has the same effect as if the signatures on the counterparts were on a single copy of this letter. 

 

		6.	This letter is a Finance Document. 

 

		7.	The provisions of clause 46 (Governing law) and
clause 47 (Enforcement) of the Facilities Agreement are incorporated into this letter as though they were set out in full,
except that references to the Facilities Agreement are to be construed as references to this letter.

 

Yours faithfully

 

	/s/ Chris Ketchen

for and on behalf of

Barclays Bank PLC

as Facility Agent, for itself and on behalf of each of the Finance Parties

 

 

 

Barclays Bank PLC, Authorised by the Prudential
Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority

Registered in England, Registered No. 1026167, Registered office: 1 Churchill Place, London E14 5HP  

    

    2

    

 

SHIRE PLC CONSENT REQUEST APPROVAL
NOTICE SIGNATURE PAGE

 

 

Acknowledged
and agreed

 

 

 

	/s/ Jeff Poulton

for and on behalf of

Shire plc

 

 

 

	/s/ Tom Greene

for and on behalf of

Shire Global Finance

 

 

 

	/s/ Tom Greene

for and on behalf of

Shire Biopharmaceuticals Holdings

 

 

 

	/s/ Leo de Waal

for and on behalf of

Shire Holdings Europe No. 2 S.à r.l.

 

 

 

	/s/ Leo de Waal

for and on behalf of

Shire Holdings Luxembourg S.à r.l.

 

 

 

	/s/ Michael Garry

for and on behalf of

Shire Pharmaceutical Holdings Ireland Limited

 

 

 

 

 

	Date: 25th November
2015	532294668

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]